False
Irv Arons’ Journal is a well-read blog that reports on new drugs and devices for the treatment of retinal diseases, including age-related macular degeneration (AMD). Until his retirement, Irv was a consultant to the ophthalmic and medical laser industries, working for management consultants Arthur D. Little for 25 years and running his own company, Spectrum Consulting, for 11 years.
January 15, 2016
Imagine being able to edit, delete or replace defective genes. It’s happening in research labs, and will soon head to the clinic
1 min read
May 11, 2015
Gene and stem cell therapies hold the promise of restoring vision in patients with retinal diseases – but who should be paying for these treatments, and how?
1 min read
November 6, 2015
Optogenetics holds the potential of reversing blindness in retinal disease – but how far has the field come, and who are the key players?
1 min read
January 21, 2014
The EMA approved the first gene therapy agent in 2012 – for lipoprotein lipase deficiency. Might gene therapies for ophthalmic disease reach the wards any time soon?
1 min read
December 3, 2013
Despite decades of research, stem cell therapies have yet to be licensed for ophthalmic use. Where does the field currently stand? We present a graphical representation of all currently ongoing clinical trials in this therapeutic area.
1 min read
Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.
False